Goldman Sachs
CRBU icon

Goldman Sachs’s Caribou Biosciences CRBU Stock Holding History

Goldman Sachs’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$568K Sell
322,875
-53,714
-14% -$106K ﹤0.01% 5619
2026
Q1 		$716K Sell
376,589
-112,549
-23% -$193K ﹤0.01% 5334
2025
Q4 		$778K Buy
489,138
+244,314
+100% +$513K ﹤0.01% 5303
2025
Q3 		$570K Sell
244,824
-546,792
-69% -$1.03M ﹤0.01% 5428
2025
Q2 		$997K Sell
791,616
-31,224
-4% -$30.7K ﹤0.01% 4709
2025
Q1 		$751K Sell
822,840
-247,696
-23% -$322K ﹤0.01% 4915
2024
Q4 		$1.7M Buy
1,070,536
+369,644
+53% +$743K ﹤0.01% 4426
2024
Q3 		$1.37M Sell
700,892
-487,872
-41% -$999K ﹤0.01% 4424
2024
Q2 		$1.95M Buy
1,188,764
+585,862
+97% +$1.87M ﹤0.01% 3946
2024
Q1 		$3.1M Sell
602,902
-57,138
-9% -$352K ﹤0.01% 3515
2023
Q4 		$3.78M Buy
660,040
+264,431
+67% +$1.31M ﹤0.01% 3393
2023
Q3 		$1.89M Buy
395,609
+124,968
+46% +$775K ﹤0.01% 3814
2023
Q2 		$1.15M Sell
270,641
-43,128
-14% -$194K ﹤0.01% 4253
2023
Q1 		$1.67M Sell
313,769
-39,128
-11% -$244K ﹤0.01% 4004
2022
Q4 		$2.22M Sell
352,897
-215,432
-38% -$1.92M ﹤0.01% 3866
2022
Q3 		$6M Buy
568,329
+428,011
+305% +$3.99M ﹤0.01% 2981
2022
Q2 		$761K Sell
140,318
-139,140
-50% -$1.06M ﹤0.01% 4807
2022
Q1 		$2.57M Buy
279,458
+247,735
+781% +$2.61M ﹤0.01% 4009
2021
Q4 		$478K Buy
+31,723
New +$617K ﹤0.01% 5418

Other funds holding CRBU

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs's CRBU Position: Q2 2026 in Review

Goldman Sachs reduced its Caribou Biosciences (CRBU) stake by 14% in Q2 2026, selling an estimated $106K and leaving 322,875 shares worth $568K. The position accounts for ﹤0.01% of the portfolio, ranked #5619.

Goldman Sachs first reported a position in CRBU in Q4 2021 and has held it in 19 quarters since. The position peaked at $6M in Q3 2022. 137 funds tracked by Wall St. Rank hold CRBU as of Q2 2026.

  • Goldman Sachs held 322,875 shares of Caribou Biosciences worth $568K as of Q2 2026.
  • Goldman Sachs sold 53,714 Caribou Biosciences shares in Q2 2026, an estimated $106K.
  • Caribou Biosciences made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5619 holding.
  • Goldman Sachs first reported a position in Caribou Biosciences in Q4 2021 and has held it in 19 quarters since.
  • Goldman Sachs's Caribou Biosciences position peaked at $6M in Q3 2022.
  • 137 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.